# Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

> **NCT02273596** · PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Wilson Disease

## Interventions

- **DRUG:** ALXN1840

## Key facts

- **NCT ID:** NCT02273596
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-24
- **Primary completion:** 2016-10-27
- **Final completion:** 2018-11-07
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273596, "Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02273596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*